New Possibilities in Systemic Treatment for Metastatic Bladder Cancer

摘要: Transitional cell carcinoma of the urothelium is a chemosensitive malignancy. It well established that combination chemotherapy routinely alters natural history both locally unresectable and metastatic disease. Unfortunately, substantial clinical advances in treatment urothelial cancer with cytotoxics have not been apparent since advent therapy generation ago. Despite high response rates, appearance second, third, even fourth-line regimens produce objective responses, median survival patients has consistently reported range 12–14 mo. Even though this more than double expectation no therapy, reliable, palliative benefit beyond question, systemic cytotoxic agents nonetheless stranded on very modest plateau (1).